Thrombolytic therapy represents one of the most time-critical interventions in modern medicine. When a coronary artery or cerebral vessel is occluded by a thrombus, the race against time begins. Two agents dominate clinical practice globally: Streptokinase (SK) and Alteplase (rt-PA). Understanding their differences is critical for optimal patient outcomes.
1Mechanism of Action
Streptokinase is an indirect thrombolytic — it combines with plasminogen to form an activator complex that converts other plasminogen molecules to plasmin, causing systemic fibrinogenolysis. Alteplase (recombinant tissue plasminogen activator, rt-PA) is fibrin-selective — it preferentially binds to fibrin within a clot and activates clot-bound plasminogen, resulting in localized clot dissolution with minimal systemic effects.
2Clinical Efficacy in STEMI
The landmark GUSTO trial demonstrated that alteplase with accelerated dosing achieves superior TIMI-3 flow rates (54%) compared to streptokinase (~32%). This translates to a 14% relative reduction in 30-day mortality with alteplase. Streptokinase remains clinically relevant — GISSI and ISIS-2 trials established its mortality benefit in STEMI, and in low-resource settings where alteplase cost is prohibitive, streptokinase remains a valuable, life-saving option.
3Safety Profile
The most feared complication is intracranial hemorrhage (ICH). Alteplase carries a slightly higher ICH risk (~0.7%) compared to streptokinase (~0.4%). Streptokinase uniquely carries a risk of allergic reactions and anaphylaxis (~1.7%) due to its Streptococcal origin. Critically, repeat use of streptokinase within 5 years is contraindicated due to neutralizing antibody formation. Both agents share contraindications including recent surgery, active bleeding, uncontrolled hypertension, and prior hemorrhagic stroke.
4Use in Acute Ischemic Stroke
In acute ischemic stroke, alteplase is the evidence-based standard of care (within 4.5 hours of onset, per NINDS and ECASS-3 trials). Streptokinase is NOT indicated for ischemic stroke — clinical trials showed unacceptable hemorrhagic transformation rates. The newer agent tenecteplase (TNK) is emerging as a convenient single-bolus alternative to alteplase in both STEMI and ischemic stroke.
5Pharmacoeconomic Considerations
Cost is a significant differentiating factor. Streptokinase costs ~₹1,500–3,000 per dose in India compared to alteplase at ~₹25,000–40,000. This 10–15× cost differential influences treatment decisions in resource-limited settings. Given this economic reality, streptokinase remains on the WHO Essential Medicines List and India's NLEM as the preferred thrombolytic for STEMI in government hospitals.
6Clinical Pharmacist's Role
Clinical pharmacists play a vital role in thrombolytic therapy management: ensuring appropriate patient selection (checking contraindications), verifying dosing and preparation protocols, monitoring for hemorrhagic complications, and educating patients on post-thrombolysis anticoagulation. At CVX Pharmacy, we emphasize comprehensive medication review as part of our MTM program, ensuring optimal evidence-based secondary prevention therapy.
Quick Comparison: Streptokinase vs Alteplase
| Feature | Streptokinase | Alteplase (rt-PA) |
|---|---|---|
| Mechanism | Indirect (complex formation) | Direct (fibrin-specific) |
| Fibrin Selectivity | Non-selective | Fibrin-selective |
| TIMI-3 Flow (STEMI) | ~32% | ~54% |
| ICH Risk | ~0.4% | ~0.7% |
| Allergic Reactions | Yes (~1.7%) | Rare |
| Repeat Dosing | Contraindicated <5 yrs | No restriction |
| Use in Stroke | Not recommended | Standard of care |
| Cost (India) | ₹1,500–3,000 | ₹25,000–40,000 |
| WHO NLEM Listed | Yes | Yes |
Conclusion
Both streptokinase and alteplase remain important therapeutic tools in the management of thromboembolic emergencies. The choice involves weighing clinical efficacy, safety profile, patient history, and healthcare resource availability. The evolving landscape of thrombolytic therapy continues to improve outcomes for patients with life-threatening thrombotic events.
CVX Pharmacy Clinical Note
This article is for educational purposes. If you or a loved one has a history of cardiac events, speak with our clinical pharmacist about your secondary prevention medication regimen during your next visit or via WhatsApp.
Chat with our pharmacist